Wall Street Zen Downgrades Vaxcyte Stock to 'Strong Sell'

Analysts cite concerns over the biotech company's latest developments

Apr. 12, 2026 at 5:12am

Got story updates? Submit your updates here. ›

An extreme close-up of industrial machinery components in shades of grey, bronze, and black, conveying the complex, high-stakes nature of the biotech industry without using any text or identifiable elements.The downgrade of Vaxcyte's stock rating underscores the high-stakes, high-pressure environment of the biotech industry, where innovative therapies face intense scrutiny.San Carlos Today

Investment firm Wall Street Zen has downgraded its rating on Vaxcyte (NASDAQ:PCVX) stock from 'sell' to 'strong sell', citing worries over the company's recent progress. The move comes as other analysts have maintained a 'Moderate Buy' consensus on the biotech firm, which is developing a new generation of preventive vaccines.

Why it matters

Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine aimed at protecting against 24 strains of Streptococcus pneumoniae. The company's stock performance and analyst sentiment can signal broader trends in the vaccine development space, which has seen increased investor attention and regulatory scrutiny in recent years.

The details

In its report, Wall Street Zen said it lowered Vaxcyte's rating due to concerns over the company's latest developments. Other analysts, however, have maintained a 'Moderate Buy' consensus on the stock, with some even increasing their price targets in recent months. Vaxcyte's shares closed at $60.88 on Friday, giving the company a market capitalization of $8.76 billion.

  • Vaxcyte stock has traded between $27.80 and $65.00 over the past 52 weeks.
  • The company reported its latest quarterly earnings on February 24, 2026.

The players

Wall Street Zen

An investment research firm that has downgraded Vaxcyte's stock rating to 'strong sell'.

Vaxcyte

A clinical-stage biotechnology company focused on developing a new generation of preventive vaccines, including its lead candidate VAX-24.

Got photos? Submit your photos here. ›

What they’re saying

“We must reevaluate Vaxcyte's prospects given the latest developments and concerns over the company's progress.”

— Wall Street Zen Analyst

What’s next

Investors will be closely watching Vaxcyte's upcoming milestones and regulatory updates as the company continues to advance its pipeline of vaccine candidates.

The takeaway

The mixed analyst sentiment on Vaxcyte reflects the broader challenges and uncertainties facing the vaccine development industry, where innovative therapies must navigate a complex regulatory landscape and evolving market dynamics.